Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

被引:2
|
作者
Halfdanarson, Thorvardur R. [1 ]
Mallak, Nadine [2 ]
Paulson, Scott [3 ]
Chandrasekharan, Chandrikha [4 ]
Natwa, Mona [5 ]
Kendi, Ayse Tuba [1 ]
Kennecke, Hagen F. [6 ]
机构
[1] Mayo Clin, Rochester, MN 55905 USA
[2] Oregon Hlth & Sci Univ, Div Mol Imaging & Therapy, Portland, OR 97239 USA
[3] Texas Oncol, Dallas, TX 75230 USA
[4] Univ Iowa Carver, Coll Med, Iowa City, IA 52242 USA
[5] NYU, Langone Hlth, New York, NY 10016 USA
[6] Providence Canc Inst Franz Clin, Portland, OR 97213 USA
关键词
radioligand therapy; peptide receptor radionuclide therapy; neuroendocrine tumor; response; monitoring; surveillance; positron emission tomography; PET; imaging; somatostatin receptor; RECEPTOR RADIONUCLIDE THERAPY; SOCIETY CONSENSUS GUIDELINES; GA-68-DOTATATE PET/CT; MEDICAL-MANAGEMENT; LU-177-DOTATATE; SURVIVAL; PRRT; HEPATOTOXICITY; Y-90-DOTATOC; PREDICTION;
D O I
10.3390/cancers15194836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Radioligand therapy with [177Lu]Lu-DOTA-TATE is a therapeutic option for adult patients with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients undergoing radioligand therapy require diligent monitoring and surveillance. While published guidelines can provide guidance on general approaches to care, GEP-NETs are heterogeneous and the guidelines can be difficult to apply in individual and complex cases. In this article, we discuss emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving radioligand therapy for GEP-NETs as well as our own best practices. We offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.Abstract Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Medicinal therapy of metastasized neuroendocrine tumors of the gastroenteropancreatic system
    Auernhammer, C. J.
    Spitzweg, C.
    Heinemann, V.
    Goeke, B.
    INTERNIST, 2012, 53 (02): : 167 - 176
  • [22] Gastroenteropancreatic neuroendocrine tumors. Targeted diagnostics and therapy
    Holzer, K.
    CHIRURG, 2014, 85 (08): : 731 - 742
  • [23] Radiopeptide therapy: the "Mustang" of treatment for gastroenteropancreatic neuroendocrine tumors
    Gabriel, Michael
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2018, 11 (03): : 81 - 85
  • [24] Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Kwekkeboom, Dik J.
    de Herder, Wouter W.
    Krenning, Eric P.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2011, 40 (01) : 173 - +
  • [25] Salvage therapy with 177Lu-octreotate in patients with gastroenteropancreatic neuroendocrine tumors
    Van Essen, Martijn
    Krenning, Eric
    Kam, Boen
    Kwekkeboom, Dik
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [26] Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
    Wetz, Christoph
    Ruhwedel, Tristan
    Schatka, Imke
    Grabowski, Jane
    Jann, Henning
    Metzger, Giulia
    Galler, Markus
    Amthauer, Holger
    Rogasch, Julian M. M.
    Guntinas-Lichius, Orlando
    CANCERS, 2023, 15 (24)
  • [27] Radioligand Therapy in Patients with Lung Neuroendocrine Tumors: A Systematic Review on Efficacy and Safety
    Malandrino, Pasqualino
    Feola, Tiziana
    Mikovic, Nevena
    Cannavale, Giuseppe
    Di Molfetta, Sergio
    Altieri, Barbara
    Mancini, Camilla
    Ferolla, Piero
    Colao, Annamaria
    Faggiano, Antongiulio
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (04) : 570 - 580
  • [28] Classification of Gastroenteropancreatic Neuroendocrine Tumors
    Perren, Aurel
    Schmitt, Anja
    Komminoth, Paul
    Anlauf, Martin
    Kloeppel, Guenter
    VISZERALMEDIZIN, 2010, 26 (04): : 234 - 240
  • [29] Nutritional Complications and the Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Laing, Erin
    Kiss, Nicole
    Michael, Michael
    Krishnasamy, Meinir
    NEUROENDOCRINOLOGY, 2020, 110 (05) : 430 - 441
  • [30] Survival of Patients With Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus
    Thapi, Sahityasri
    Baeg, Kiwoon
    Kim, Michelle K.
    Gallagher, Emily J.
    PANCREAS, 2021, 50 (09) : 1293 - 1297